Angela Queisser
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Angela Queisser has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Laurence Myriam Boon
Center for Vascular Anomalies, Division of Plastic Surgery, VASCERN VASCA European Reference Centre, Saint Luc University Hospital, Avenue Hippocrate 10, 1200 Brussels, Belgium
2 shared publications - Miikka Vikkula
Human Molecular Genetics, de Duve Institute, UCLouvain, Brussels, Belgium
2 shared publications - An-Katrien De Roo
Department of Pathology Cliniques Universitaires Saint‐Luc Brussels Belgium
1 shared publication - Anne Dompmartin
Dermatology Department, CHU Caen, Caen, France
1 shared publication Anne Offermann
Pathology of the University Hospital of Lübeck and Leibniz Research Center Borstel, Lübeck and Borstel, Germany
1 shared publicationAnne Schindler
Institute of Pathology, University Hospital of Bonn, Bonn, Germany
1 shared publication
Latest Publications
- Open Access
- 29 February 2024
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 144 (9) , 2066-2077.e6
Somatic Loss-of-Function PIK3R1 and Activating Non-hotspot PIK3CA Mutations Associated with Capillary Malformation with Dilated Veins (CMDV)
- 29 February 2024
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 144 (9) , 2066-2077.e6
Open AccessSomatic Loss-of-Function PIK3R1 and Activating Non-hotspot PIK3CA Mutations Associated with Capillary Malformation with Dilated Veins (CMDV)
- Top Cited Papers
- 25 June 2021
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 129 (1) , 155-173
Genetic Basis and Therapies for Vascular Anomalies
Vascular and lymphatic malformations represent a challenge for clinicians. The identification of inherited and somatic mutations in important signaling pathways, including the PI3K (phosphoinositide 3-kinase)/AKT (protein kinase B)/mTOR (mammalian target of rapamycin), RAS (rat sarcoma)/RAF (rapidly accelerated fibrosarcoma)/MEK (mitogen-activated protein kinase kinase)/ERK (extracellular signal-regulated kinases), HGF (hepatocyte growth factor)/c-Met (hepatocyte growth factor receptor), and VEGF (vascular endothelial growth factor) A/VEGFR (vascular endothelial growth factor receptor) 2 cascades has led to the evaluation of tailored strategies with preexisting cancer drugs that interfere with these signaling pathways. The era of theranostics has started for the treatment of vascular anomalies. Registration: URL: https://www.clinicaltrialsregister.eu ; Unique identifier: 2015-001703-32.
- 25 June 2021
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 129 (1) , 155-173
Top Cited PapersGenetic Basis and Therapies for Vascular Anomalies
Vascular and lymphatic malformations represent a challenge for clinicians. The identification of inherited and somatic mutations in important signaling pathways, including the PI3K (phosphoinositide 3-kinase)/AKT (protein kinase B)/mTOR (mammalian target of rapamycin), RAS (rat sarcoma)/RAF (rapidly accelerated fibrosarcoma)/MEK (mitogen-activated protein kinase kinase)/ERK (extracellular signal-regulated kinases), HGF (hepatocyte growth factor)/c-Met (hepatocyte growth factor receptor), and VEGF (vascular endothelial growth factor) A/VEGFR (vascular endothelial growth factor receptor) 2 cascades has led to the evaluation of tailored strategies with preexisting cancer drugs that interfere with these signaling pathways. The era of theranostics has started for the treatment of vascular anomalies. Registration: URL: https://www.clinicaltrialsregister.eu ; Unique identifier: 2015-001703-32.
- Open Access
- 30 March 2016
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (17) , 23043-23055
Comprehensive analysis of the transcriptional profile of the Mediator complex across human cancer types
The Mediator complex is a key regulator of gene transcription and several studies demonstrated altered expressions of particular subunits in diverse human diseases, especially cancer. However a systematic study deciphering the transcriptional expression of the Mediator across different cancer entities is still lacking.
- 30 March 2016
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (17) , 23043-23055
Open AccessComprehensive analysis of the transcriptional profile of the Mediator complex across human cancer types
The Mediator complex is a key regulator of gene transcription and several studies demonstrated altered expressions of particular subunits in diverse human diseases, especially cancer. However a systematic study deciphering the transcriptional expression of the Mediator across different cancer entities is still lacking.